Business
Intensity Therapeutics Reports 2025 Year End Financial Results and Highlights, and Provides Corporate Update
Raised over $20 million in gross proceeds in 2025 and held $11.9 million in cash and cash equivalents as of December 31, 2025, with a cash runway into the
About this update from Intensity Therapeutics, Inc.
[{"type":"text","content":"Raised over $20 million in gross proceeds in 2025 and held $11.9 million in cash and cash equivalents as of December 31, 2025, with a cash runway into the second quarter of 2027IT-01 Study manuscript of INT230-6 used alone in 64 refractory metastatic cancer patients published in the Lancet's journal eBioMedicine, including data for disease control rate, overall survival, immune activation, abscopal effects, tumor necrosis, dose ranging, and safetyFavorable efficacy and safety reported in a small sample of triple negative breast cancer (\"TNBC\") patients receiving INT230-6 prior to the standard of care (\"SOC\") compared to SOC alone in the INVINCIBLE-4 StudySHELTON, Conn., March 27, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc. (\"Intensity\" or \"the Company\") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill tumors and increase immune system recognition of cancers using its proprietary non-covalent conjugation technology, announces 2025 year-end financial results and highlights, and provides a corporate update.\n \n \n \n \n \n \n \nCorporate UpdateINVINCIBLE-4 Study: Phase 2 randomized open-label, multicenter study to analyze the clinical activity, safety, and tolerability of INT230-6 given before administration of the SOC treatment in patients with early-stage, operable triple negative breast cancer and SOC alone.In March 2026, the Company reported the following:Preliminary observations of the INVINCIBLE-4 Study showed that five (5) out of seven (7) patients (71.4%) who received INT230-6 prior to SOC (\"Cohort A\") achieved a pathological complete response (\"pCR\") whereas two (2) out of six (6) (33%) patients in the SOC arm alone (\"Cohort B\") achieved a pCR, with one patient still to be evaluated.Forty-four percent (44%) fewer grade 3 or higher adverse events were observed in Cohort A compared to Cohort B.A protocol amendment was submitted to Swissmedic, Switzerland's regulatory authority, and the Switzerland Ethics Committee to resume enrollment. Full approval to resume enrollment was granted on March 26, 2026.The Company expects presentation of more detailed results for the seven (7) Cohort A patients at a future oncology conference.INVINCIBLE-3 Study: Phase 3 open-label, randomized study testing IN...